Geron Corporation Initiates Clinical Trial of GRN163L in Combination with Paclitaxel and Bevacizumab in Patients with Breast Cancer

August 7, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced the enrollment of the first patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in locally recurrent or metastatic breast cancer.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase I